Landmark Trial of Abbott's (ABT) MitraClip(R) System Shows Heart-Valve Clamp Safer Than Surgery

Abbott (NYSE: ABT) says a landmark clinical trial of its MitraClip(R) System demonstrates that the heart-valve clamp is safer than surgery. Data shows a success rate of 51.7% vs. surgery success of 66.3%.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Wolfe Research Upgrades Abbott Labs (ABT) to Outperform
• Mosaic sets pricing for tender offers on up to $1.4B in debt
• Cable One names Heather McCallion as chief operating officer